



Napp's charter on the responsible medical use of opioid analgesics in pain management



A member of the Mundipharma network of associated companies

Napp's charter on the responsible medical use of opioid analgesics in pain management

Opioid analgesics can be an important option for healthcare professionals to appropriately treat certain patients with pain. Notwithstanding this medical need, Napp recognises that the use of prescription opioid medications is associated with risks, including misuse, abuse, addiction (opioid use disorder, OUD), and diversion. As a company that develops, sells, and distributes opioid medicines, we are committed to reducing these risks and supporting healthcare professionals in their appropriate and responsible medical use.

When prescribing opioid analgesics, patients' individual circumstances and medical history must be carefully considered, in addition to the need to balance adequate pain relief with the risks and adverse effects associated with opioid therapy.

Regular and careful monitoring by the clinician is essential to ensure the lowest effective dose for the shortest duration is prescribed and that any continued use is clinically appropriate.

Napp and our associated companies in the Mundipharma group always acts lawfully and is committed to high ethical and scientific standards in all our business activities. This includes reducing the risks of opioid therapy through appropriate medical information for healthcare professionals, responsible sales and marketing practices, and a secure supply chain.

As part of this commitment, Napp and our associated companies in the Mundipharma group:

1. Strictly follows national and international laws, regulations, and guidelines governing the appropriate development, manufacture, distribution, and promotion of opioid medicines. Our Product Stewardship Committee provides an ethical framework based on these laws, regulations, and guidelines.
2. Supports healthcare professionals by providing them with fair, accurate, and balanced scientific information about opioid analgesics, including information on the associated risks and adverse effects.
3. Chooses not to promote strong opioids for the treatment of chronic non-cancer pain*. Medical education and information about the use of strong opioids in chronic non-cancer pain is only provided by our medical team in response to unsolicited requests from healthcare professionals.
4. Does not support the off-label, inappropriate, or non-medical use of opioid analgesics.
5. Maintains strict global governance, which follows applicable laws and codes, for all our activities and materials, including mandatory compliance and medical training of all employees who interact with healthcare professionals regarding opioid analgesics. In addition, all Napp and our associated companies in the Mundipharma group employees, regardless of role, undertake mandatory opioid awareness training.
6. Assesses the effectiveness of our governance through regular auditing and monitoring.
7. Assesses and audits our supply chains to reduce the risk of diversion or loss, and continually improves the security of the supply chain.
8. Promotes and actively manages our [Mundipharma Integrity Line](#) to enable anyone to report issues or concerns without fear of retaliation and with the assurance that all reports will be promptly investigated and that confirmed violations will be addressed through appropriate actions.

* Apart from the seven-day, low dose, transdermal buprenorphine patch.